Loxoprofen
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral, transdermal |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 97% |
Metabolism | Liver glucuronidation |
Elimination half-life | 75 minutes |
Excretion | Kidney |
Identifiers | |
| |
JSmol) | |
Chirality | Racemic mixture |
| |
| |
(what is this?) (verify) |
Loxoprofen is a nonsteroidal anti-inflammatory drug (NSAID) in the propionic acid derivatives group, which also includes ibuprofen and naproxen among others. It is available in some countries for oral administration. A transdermal preparation was approved for sale in Japan in January 2006;[1] medicated tape and gel formulations followed in 2008 and 2010.
It was patented in 1977 and approved for medical use in 1986.[2]
Pharmacokinetics
Loxoprofen is a prodrug. It is quickly converted to its active trans-alcohol metabolite following oral administration, and reaches its peak plasma concentration within 30 to 50 minutes.
Mechanism of action
As most
Interactions
Loxoprofen should not be administered at the same time as second-generation
It may also increase the plasma concentration ofBrand names
It is marketed in Brazil, Mexico, China and Japan by Sankyo as its sodium salt, loxoprofen sodium, under the trade name Loxonin; in Argentina as Oxeno; in India as Loxomac; in Thailand as Japrolox; and in Saudi Arabia as Roxonin and Roxonin Tape.
A
References
- Daiichi Sankyo Co. (January 24, 2006). "Percutaneous Absorption-Type Analgesic and Anti-inflammatory Drug Loxonin Poultice 100mg Receives Approval for Manufacture"(Press release). Doctor's Guide Global Edition. Retrieved 2007-04-19.
- ISBN 9783527607495.
- ^ a b "LOXONIN - Bula do Medicamento [Label Information]" (in Portuguese). Centralx. 2007. Retrieved 2007-04-19.